Stability of the latent reservoir for HIV-1 in patients receiving valproic acid.
In light of a recent report that short-term treatment with valproic acid (VA) might accelerate the decay of the latent reservoir for HIV-1 in patients receiving combination therapy and allow eventual eradication of the infection, we studied patients with prolonged suppression of viremia who were receiving combination therapy and who had also been receiving chronic VA therapy for neurological or psychiatric conditions. Latently infected cells were readily detected in all patients at levels comparable to those seen in patients receiving combination therapy alone. We conclude that the clinical use of VA has no ancillary effect on the decay of the latent reservoir.
Siliciano
Janet D
JD
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA. rsiliciano@jhmi.edu
Lai
Jun
J
Callender
Marc
M
Pitt
Eleanor
E
Zhang
Hao
H
Margolick
Joseph B
JB
Gallant
Joel E
JE
Cofrancesco
Joseph
J
Moore
Richard D
RD
Gange
Stephen J
SJ
Siliciano
Robert F
RF
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D004197:Disease Reservoirs; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D008213:Lymphocyte Activation; D014635:Valproic Acid / Q000627:therapeutic use*; D014779:Virus Replication / Q000187:drug effects*
D014635:Valproic Acid